Tasigna gets Swiss nod as first-line drug

Novartis' Tasigna won its first European approval as a first-line treatment when Swiss authorities green-lighted the blood cancer drug after a fast-track review. Novartis release | Report

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.